Bristol-Myers Squibb acquires Cormorant Pharmaceuticals
Gains full-rights to Cormorant’s HuMax-IL8 antibody program and lead asset HuMax-IL8 in Phase 1/2 Development
06-Jul-2016 -
Bristol-Myers Squibb Company and Cormorant Pharmaceuticals announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The ...
acquisitions
Bristol-Myers Squibb
interleukins
+1